Working… Menu

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03626623
Recruitment Status : Terminated (Sponsor Discretion)
First Posted : August 13, 2018
Results First Posted : February 15, 2021
Last Update Posted : February 15, 2021
Information provided by (Responsible Party):
Integra LifeSciences Corporation

Brief Summary:
This is a two-armed randomized controlled trial (RCT) primarily aimed at determining if application of Cytal Wound Matrix 1-Layer intervention to diabetic foot ulcers shows improved wound closure rates when compared to standard care intervention.

Condition or disease Intervention/treatment Phase
Diabetes Diabetic Foot Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 Device: Cytal Wound Matrix 1-Layer Other: Standard of Care (SOC) Not Applicable

Detailed Description:

This is a prospective, two-armed, multi-center randomized controlled trial (RCT) comparing Cytal Wound Matrix 1-Layer intervention to standard of care (SOC) intervention in patients presenting with diabetic foot ulcers (DFU). Up to one hundred and fifty patients recruited from US based medical centers and randomized (using a 2(active):1(control) randomization scheme) to receive either Cytal Wound Matrix 1-Layer intervention or standard of care intervention.Complete wound closure incidence, wound healing rates, wound recurrence, and various health related quality of life (HRQOL) outcomes will be compared between study arms. Additionally, a cost effective analysis (i.e. direct and indirect costs) and review of individual and group changes in narcotic prescription patterns will also be evaluated. While incidence of wound closure rates will be evaluated through 12 weeks, protocol defined patient follow-up is for two years.

Data will be captured for remaining study objectives during these two years. An independent biostatistician will review all participant data for power and futility analysis. In addition, a clinical events committee (CEC) will adjudicate all adverse events (AEs) and serious adverse events (SAEs).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Trial Comparing Cytal Wound Matrix 1-Layer to Standard of Care (SOC) in the Management of Diabetic Foot Ulcers (DFUs)
Actual Study Start Date : May 21, 2019
Actual Primary Completion Date : February 18, 2020
Actual Study Completion Date : February 18, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Standard of Care (SOC)
The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
Other: Standard of Care (SOC)
Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.

Active Comparator: Cytal Wound Matrix 1-Layer
The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
Device: Cytal Wound Matrix 1-Layer
Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.

Primary Outcome Measures :
  1. Incidence of Wound Closure [ Time Frame: up to 12 weeks ]
    The primary endpoint of the study is to measure the incidence of complete wound closure (defined as 100% epithelialization) between randomized groups.

Secondary Outcome Measures :
  1. Wound Size Change [ Time Frame: up to 12 weeks ]
    Measure changes in wound size, measured in cm2/week between randomized groups.

  2. Complete Wound Closure Time [ Time Frame: up to 12 weeks ]
    Measure time to complete wound closure between randomized groups.

  3. Wound Recurrence [ Time Frame: at 26 week visit and 52 week visit ]
    Measure wound recurrence after healing is complete between randomized groups.

  4. Short Form-20 (SF-20) [ Time Frame: Baseline visit, visit #7, visit #13, 26 wk. visit, and 52 wk.visit ]
    The Short Form-20 is a 20-item questionnaire used to assess generic health outcomes from the participant's perspective. Scores are linearly measured from 0 (worst) to 100 (best) health functioning scores, respectively.

  5. Diabetic Foot Ulcer Scale- Short Form (DFS-SF) [ Time Frame: Baseline visit, 26 week visit, and 52 week visit ]
    The diabetic foot ulcer scale- short form (DFS-SF) is a 29-item questionnaire designed to assess the impact of diabetic foot ulcers (DFUs) and their intervention on quality of life of participants diagnosed with diabetes. Scores measured from 0 (lower) to 100 (higher) quality of life, respectively.

  6. Visual Analogue Scale (VAS) for Pain [ Time Frame: Up to 52 week visit (until study completion) ]
    The visual analogue scale (VAS) is a psychometric response scale for pain. It measures subjective characteristics or attitudes regarding perceived pain levels from participants. Participants are asked to draw a vertical line on a 10 cm horizontal line indicating what their current pain level would be. The distance between the start of the horizontal line to the vertical line is calculated in cm with a higher score (100) indicating greater pain intensity.

  7. Katz Index of Independence in Activities of Daily Living (KATZ ADL) [ Time Frame: Baseline visit, visit 7, visit 13, 26 wk visit, and 52 wk visit ]
    The Katz ADL is a 6-item questionnaire measuring independence in activities of daily living such as bathing, dressing, toileting, transfers, feeding, and continence. Each item is dichotomized as either having a score of zero (i.e. dependence) or one (i.e. independence). This will be completed with the aid of a trained study staff member.

  8. Adverse Events Frequency [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures diabetic foot ulcer (DFU) related adverse event frequency including unexpected adverse device events (UADEs) or serious adverse experiences (SAEs) throughout the duration of the study as well as evaluate such adverse event frequencies between randomized groups.

  9. Narcotic Prescription Changes Between Trial Arms [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures changes in number of diabetic foot ulcer (DFU) related narcotic prescriptions by study participant and between randomized groups.

  10. Participant Ambulatory Status [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures any changes in ambulatory status (i.e. bed, wheel chair, walk w/ assistance, or walk independent) by study participant and between randomized groups.

  11. Return to Work Status [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures differences in "return to work status" and/or "reported work status", activities of daily living, or disability status by study participant and between randomized groups.

  12. Diabetic Foot Ulcer (DFU) Specific Ancillary Medical Care [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures the incidence of diabetic foot ulcer (DFU) specific related medical care a study participant receives outside of the medical care provided by the investigator. Examples of ancillary care include, but are not limited to, emergency room (ER) visits, urgent care visits, outside medical procedures such as surgery, etc. The incidence of subjects requiring ancillary medical care will be tabulated and compared between randomized groups. This data will be collected via two questions (i.e. "Did participant receive any ancillary medical care?" and "If "yes", then specify where"). Responses are verified using source documentation.

  13. Diabetic Foot Ulcer (DFU) Related Direct Product(s) Costs [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures direct costs of the products by total cost per subject stratified by healed vs. non healed DFU.

  14. Indirect Diabetic Foot Ulcer (DFU) Product(s) Costs [ Time Frame: up to 52 week visit (until study completion) ]
    This outcome measures total indirect and incidental costs of diabetic foot ulcer products used per study participant by each visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision of signed and dated informed consent form by subject or legally authorized representative.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study. Subject is able and willing to tolerate non-removable offloading device for the duration of the run-in and intervention phases of the study.
  3. Subject is male or female and at least 21years of age.
  4. Subject has a clinical diagnosis of type 1 or type 2 diabetes.
  5. Subject's current foot ulcer(s) has been present for > 30 days and ≤ 365 days.
  6. Subject's current foot ulcer(s), post-debridement is/are predominantly below the malleoli and on the plantar surface of the foot.
  7. Subject's foot ulcer(s) must be Wagner type 1 or type 2.
  8. Post debridement, subject's ulcer(s) are free of necrotic debris and appear to be comprised of healthy, vascularized tissue.
  9. All qualifying ulcers are ≥ 5cm away from any other ulcer on the same foot.
  10. Subject's ulcer(s) is ≥ 1cm2 and ≤ 20cm2 at randomization (length x width).
  11. Subject's HbA1C reading is ≤10%.
  12. Subject's Serum Creatinine ≤ 3.0mg/dL.
  13. Subject has adequate circulation to the foot as measured by Ankle-Brachial Index (ABI) ≥ 0.7.
  14. Negative pregnancy test at randomization for women.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Subject is pregnant, breastfeeding, or unwilling to practice birth control during participation in the study, if applicable.
  2. Allergy or hypersensitivity to materials in porcine-based study products (per subject report) or personal preference.
  3. Subject report of concurrent participation in another clinical trial that involves a drug.
  4. The subject has any condition that, in the Investigator's opinion, would warrant exclusion from the study or prevent the subject from completing the study.
  5. Subject has clinical evidence of gangrene on any part of the affected foot.
  6. The subject's ulcer(s) is/are due to a non-diabetic etiology, ulcers of arterial, venous stasis, pressure, radiation, traumatic, rheumatoid, vasculitis, collagen vascular disease, or other non-diabetic etiologies.
  7. Subject has unstable Charcot foot, Charcot foot with a bony prominence(s) or Charcot amputation.
  8. Qualifying wound(s) is connected to another ulcer via a fistula.
  9. Subject has one or more medical condition(s) including: renal, hepatic, hematological, neurologic, or immune disease that in the opinion of the Investigator would make the subject an inappropriate candidate for this wound healing study.
  10. Subject has or has had a malignant disease (other than basal cell carcinoma) that has not been in remission for at least five years.
  11. Subject is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such during the course of the study.
  12. Subject has acute osteomyelitis of the affected foot.
  13. Subject's ulcer(s) is accompanied by active cellulitis.
  14. Subject has received growth factor or enzymatic therapy within 2 weeks of consent.
  15. Subject is currently receiving or has received radiation, radiologic implants, or chemotherapy.
  16. Subject is allergic to any of the primary or secondary dressing materials, including occlusive dressings and the adhesives on such dressings.
  17. Subject's ulcer(s) has decreased in size by >30% during the run-in phase.
  18. Subject's ulcer(s) has increased in size by >50% during the run-in phase.
  19. Subject's ulcer(s) has tunnels or sinus tracts that cannot be completely debrided.
  20. Subject has severe malnutrition as evidenced by albumin <2.0 g/dL.
  21. Subject has a bleeding disorder as documented by a diagnosis of a bleeding disorder.
  22. Subject is on dialysis.
  23. Any DFU(s) is infected and has not been treated for any clinically suspected infection prior to application of any product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03626623

Layout table for location information
United States, California
Limb Preservation Platform, Inc.
Fresno, California, United States, 93710
United States, Louisiana
Louisiana State University Health Science Center (LSUHSC)
New Orleans, Louisiana, United States, 70112
United States, Maryland
MedStar Health Research Institute
Hyattsville, Maryland, United States, 20782
Sponsors and Collaborators
Integra LifeSciences Corporation
Layout table for investigator information
Study Chair: Allison Matthews Integra LifeSciences Corporation
  Study Documents (Full-Text)

Documents provided by Integra LifeSciences Corporation:
Additional Information:
Layout table for additonal information
Responsible Party: Integra LifeSciences Corporation Identifier: NCT03626623    
Other Study ID Numbers: CR2017-006
First Posted: August 13, 2018    Key Record Dates
Results First Posted: February 15, 2021
Last Update Posted: February 15, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Integra LifeSciences Corporation:
Foot Ulcer
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetic Neuropathies
Foot Diseases
Autoimmune Diseases
Immune System Diseases